. Author manuscript; available in PMC: 2011 Aug 1.

Published in final edited form as: Nat Rev Nephrol. 2010 Dec 14;7(2):85–95. doi: 10.1038/nrneph.2010.171

Table 3.

Treatment for paraneoplastic glomerulonephritis according to type of malignancy

Malignancy	Treatment for paraneoplastic glomerulonephritis
Solid tumors	Tumor ablation, additional immunosuppression for RPGN
Lymphoid malignancies	Ablation of malignancies
Myeloid malignancies
CML	Immunosuppression for MCD and RPGN
PV, ET, PMF	Myelosuppression, phlebotomy
MDS	Immunosuppression
CMML	Ablation of malignancies
Thymoma
Epithelial predominant	Tumor ablation
Lymphocyte predominant	Immunosuppression

Abbreviations: CML, chronic myelogenous leukemia; CMML, chronic myelomonocytic leukemia; ET, essential thrombocythemia; MCD, minimal change disease; MDS, myelodysplastic syndrome; PMF, primary myelofibrosis; PV, polycythemia vera; RPGN, rapidly progressive glomerulonephritis.